SCHEMBL2556847

SCHEMBL2556847

Cc1ccc(F)cc1CC=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 5/20 0.36
HTR2A P28223 1/20 0.36
KCNH2 Q12809 1/20 0.36
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
HPGD P15428 1/20 0.35
KMT2A Q03164 1/20 0.35
P2RX7 Q99572 2/20 0.33
MEP1B Q16820 1/20 0.33
SLC6A2 P23975 4/20 0.33
SLC6A3 Q01959 4/20 0.33
NTRK1 P04629 1/20 0.32
SGMS2 Q8NHU3 1/20 0.32
FFAR1 O14842 1/20 0.32
FFAR4 Q5NUL3 1/20 0.32
KDM4E B2RXH2 1/20 0.32
PTGS1 P23219 2/20 0.32
PTGS2 P35354 2/20 0.32
ALOX5 P09917 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2562083 0.84 P2RX7 (0.38) ALDH1A1MEN1POLBKMT2AP2RX7
SCHEMBL1516538 0.80 GABRA1 (0.41) ALDH1A1POLBHPGDPTGS1
SCHEMBL20651301 0.80 GABRA1 (0.41) SLC6A4HTR2AKCNH2ALDH1A1MEN1
SCHEMBL3121227 0.79 PSEN1 (0.43) ALDH1A1MEN1POLBHPGDKMT2A
SCHEMBL29954553 0.79 PSEN1 (0.43) ALDH1A1MEN1POLBHPGDKMT2A
SCHEMBL1124970 0.79 TAAR1 (0.50) ALDH1A1MEN1POLBHPGDKMT2A
SCHEMBL8240380 0.79 SLC6A4 (0.40) SLC6A4HTR2AKCNH2P2RX7MEP1B
SCHEMBL30536248 0.77 ALDH1A1 (0.52) SLC6A4ALDH1A1MEN1POLBHPGD
SCHEMBL2689127 0.77 ALDH1A1 (0.52) SLC6A4ALDH1A1MEN1POLBHPGD
SCHEMBL2651660 0.77 SLC6A4 (0.39) SLC6A4HTR2AKCNH2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4457213-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) Psy Therapeutics, Inc. (US) 2024-11-06 EP disclosed
WO-2023130023-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) PSY THERAPEUTICS, INC. (US) 2023-07-06 WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 US disclosed
EP-3540059-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2019-09-18 EP disclosed
EP-2558577-B1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION AS (DK) 2018-12-12 EP disclosed
US-20130281324-A1 BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2013-10-24 US disclosed
EP-2558577-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2013-02-20 EP disclosed
WO-2011127933-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2011-10-20 WO disclosed
EP-1583742-A1 NOVEL CB 1 RECEPTOUR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
WO-2004060870-A1 NOVEL CB 1 RECEPTOUR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed